Clinical Report: AF Stroke Prevention: Testing Ablation

Overview

The STABLED trial found that adding catheter ablation to anticoagulation therapy did not significantly reduce recurrent stroke or other major cardiovascular outcomes among patients with atrial fibrillation and a recent ischemic stroke. The study included 251 patients and followed them for over three years, assessing a primary composite outcome of recurrent ischemic stroke, systemic embolism, all-cause death, and hospitalization for heart failure.

Background

Atrial fibrillation (AF) is a leading cause of stroke and systemic embolism, making effective stroke prevention strategies crucial. Current guidelines emphasize that oral anticoagulation is essential for secondary stroke prevention in AF patients. The role of catheter ablation as a complementary strategy remains under investigation, particularly in high-risk populations.

Data Highlights

Key Findings

• Catheter ablation did not significantly reduce the primary composite outcome compared to standard therapy (hazard ratio 1.11).
• Event rates for recurrent ischemic stroke were similar between the two groups.
• Major bleeding events were more frequent in the ablation group.
• Approximately 14% of participants crossed over between treatment groups during the study.
• Recurrent ischemic stroke occurred less frequently than expected in the anticoagulation-only group.

Clinical Implications

The findings suggest that catheter ablation may not provide additional benefits over anticoagulation alone for stroke prevention in AF patients with a recent ischemic stroke. Clinicians should continue to prioritize anticoagulation therapy while considering the risks associated with ablation and individual patient factors.

Conclusion

The STABLED trial indicates that catheter ablation does not offer a clear clinical advantage in preventing recurrent strokes in this patient population, reinforcing the importance of anticoagulation as the primary strategy for stroke prevention.

References

1. Kimura K, et al., JAMA Neurology, 2023 -- Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation: The STABLED Randomized Clinical Trial
2. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation, PMC -- Current guidelines on anticoagulation
3. Scholars@Duke publication, 2025 -- Catheter and Surgical Ablation for Atrial Fibrillation: A Systematic Review and Meta-analysis
4. Clinical Research in Cardiology — Evaluation of Arctic Front Advance Pro versus POLARx Cryoballoons in Atrial Fibrillation Ablation: An Intraprocedural Examination
5. Clinical Research in Cardiology — Outcomes and Risks Associated with Catheter Ablation for Ventricular Arrhythmias: Evaluating the VT Ablation Risk Score (RIVA)
6. Clinical Research in Cardiology — Evaluation of Treatment Approaches for Atrial Fibrillation Patients with Left Atrial Appendage Thrombus Despite Optimal NOAC Management
7. Frontiers in Cardiovascular Medicine — A study on risk factors of acute ischemic stroke after radiofrequency ablation in patients with atrial fibrillation
8. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - PMC
9. Scholars@Duke publication: Catheter and Surgical Ablation for Atrial Fibrillation : A Systematic Review and Meta-analysis.
10. Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation: The STABLED Randomized Clinical Trial | Trials | JAMA Neurology | JAMA Network